Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 38% Improvement Relative Risk c19early.org/d Shahid et al. Vitamin D for COVID-19 LATE TREATMENT Is late treatment with vitamin D beneficial for COVID-19? Retrospective 1,478 patients in the USA Lower mortality with vitamin D (p=0.001) Shahid et al., Abstracts from the 2022 Annual Me.., doi:10.1007/s11606-022-07653-8 Favors vitamin D Favors control
The effects of vitamin D therapy on outcomes for hispanic patients hospitalized for COVID-19
Shahid et al., Abstracts from the 2022 Annual Meeting of the Society of General Internal Medicine, Journal of General Internal Medicine, doi:10.1007/s11606-022-07653-8
Shahid et al., The effects of vitamin D therapy on outcomes for hispanic patients hospitalized for COVID-19, Abstracts from the 2022 Annual Meeting of the Society of General Internal Medicine, Journal of General Internal Medicine, doi:10.1007/s11606-022-07653-8
Jun 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 1,478 hospitalized Hispanic patients in the USA with 705 receiving vitamin D treatment, showing lower mortality with treatment in unadjusted results. Very minimal information is currently available.
This is the 85th of 111 COVID-19 controlled studies for vitamin D, which collectively show efficacy with p<0.0000000001 (1 in 49 sextillion). 27 studies are RCTs, which show efficacy with p=0.00002. This study is excluded in the after exclusion results of meta analysis: minimal details provided.
risk of death, 38.0% lower, RR 0.62, p < 0.001, treatment 705, control 773.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Shahid et al., 17 Jun 2022, retrospective, USA, peer-reviewed, 2 authors, dosage not specified.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Abstract: Abstracts from the 2022 Annual Meeting of the Society of General Internal Medicine J Gen Intern Med 37(Suppl 2):S129–S664 DOI: 10.1007/s11606-022-07653-8 © The Author(s), under exclusive licence to Society of General Internal Medicine 2022 THE EFFECTS OF VITAMIN D THERAPY ON OUTCOMES FOR HISPANIC PATIENTS HOSPITALIZED FOR COVID-19 Saqib Shahid1; Fatma Dihowm2 1 Department of Internal Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX 2 Internal Medicine, Texas Tech University Health Science Center, El paso, TX. (Control ID #3709726) BACKGROUND: The SARS-CoV-2 novel coronavirus that causes COVID19 has been shown to more severely affect individuals with underlying conditions, such as metabolic syndrome or diabetes. This is a reason why SARS-CoV-2 more severely affects populations at risk for these conditions, notably the Hispanic population. Vitamin D has been shown to be a positive immunomodulatory actor, shown to upregulate production of CAMP (cathelicidin antimicrobial peptide) and its effect on mitigating the severity of respiratory illnesses has been widely studied. Additionally, given vitamin D’s role in the functional regulation of pancreatic beta cells, this study aims to determine whether vitamin D plays a significant role in providing better outcomes for Hispanic patients with diabetes. Data will be gathered for patients treated at University Medical Center in El Paso, where the majority of the population treated is Hispanic, allowing us the opportunity to observe phenomena unique to this population. S194 METHODS: We collected data from the charts of 1,478 Hispanic patients who were hospitalized for COVID-19 at University Medical Center El Paso. Comparisons were made between patients who received VItamin D therapy (705) and those who did not (773). The main outcome that was assessed was mortality, as well as secondary outcomes such as length of hospital stay, need for supplemental oxygen upon discharge, and ICU admission. Further comparisons were made between patients who suffer from diabetes and those who do not. RESULTS: Our preliminary results by way of a univariate analysis show that patients who were given Vitamin D therapy during their hospitalization had significantly lower rates of mortality (p<0.001). Patients in the group that received Vitamin D therapy were 38% less likely to die during their hospital stay (p<0.001). We also discovered that patients admitted to UMC El Paso were significantly more likely to be given Vitamin D therapy if they presented with respiratory and GI symptoms (p<0.001). A multivariate analysis on the relationship between previous history of diabetes and the efficacy of Vitamin D therapy is pending. CONCLUSIONS: Our results show that Vitamin D therapy as a part of the treatment protocol for COVID-19 can significantly reduce mortality during hospitalization. As a result of the unique composition of our patient population, these findings can help build standards of practice that are applicable to the specific needs of Hispanic patients throughout the course of the pandemic. Because patients in the Hispanic population are more susceptible to severe symptoms due to their predisposition to comorbid conditions like diabetes, using protocols informed by evidence has the potential to prevent mortality on a large scale.
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit